Computational identification of self-inhibitory peptides from envelope proteins

Proteins: Structure, Function and Bioinformatics

Volumn 80, Issue 9, 2012, Pages 2154-2168

  Xu, Yongtao ^a   Rahman, Noorsaadah A B D ^b   Othman, Rozana ^b   Hu, Peijun ^a   Huang, Meilan ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Dengue virus; Envelope protein; HIV 1 gp41; HSV 1 gB; Optimization; Peptide inhibitor

Indexed keywords

CLASS II DENGUE VIRUS TYPE 2 ENVELOPE PROTEIN; CLASS III HERPES SIMPLEX VIRUS 1 GLYCOPROTEIN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 41; HYBRID PROTEIN; PEPTIDE; SELF INHIBITORY PEPTIDE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ALPHA HELIX; ARTICLE; BETA SHEET; HYDROPHILICITY; MEMBRANE FUSION; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; DENGUE VIRUS; DRUG DISCOVERY; HIV ENVELOPE PROTEIN GP41; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MONTE CARLO METHOD; PEPTIDES; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS; VIRUS INTERNALIZATION;

DENGUE VIRUS; DENGUE VIRUS TYPE 2; HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864405087     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24105     Document Type: Article

References (46)

1. Teissier E, Penin F, Pécheur EI. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules 2011; 16: 221-250.
2. Backovic M, Jardetzky TS. Class III viral membrane fusion proteins. Curr Opin Struct Biol 2009; 19: 189-196.
3. Kielian M, Rey FA. Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 2006; 4: 67-76.
4. Perera R, Khaliq M, Kuhn RJ. Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res 2008; 80: 11-22.
5. Jacobs MG, Young PR. Dengue: a continuing challenge for molecular biology. Curr Opin Infect Dis 1998; 11: 319-324.
6. Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. Mutatioanl evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 2001; 75: 4268-4275.
7. Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004; 427: 313-319.
8. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 1995; 375: 291-298.
9. Gromowski GD, Barrett ND, Barrett AD. Characterization of dengue complex-specific neutralizing epitopes on the envelope protein domain III of dengue 2 virus. J. Virol 2008; 82: 8828-8837.
10. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007; 1: 12816-12826.
11. Huang KC, Lee MC, Wu CW, Huang KJ, Lei HY, Cheng JW. Solution structure and neutralizing antibody binding studies of domain III of the dengue-2 virus envelope protein. Proteins 2008; 70: 1116-1119.
12. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 2008; 15: 312-317.
13. Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5: 276-279.
14. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151: 413-423.
15. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, Weiss CD. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003; 77: 1666-1671.
16. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, Harrison SC. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 2006; 313: 217-220.
17. London N, Raveh B, Movshovitz-Attias D, Schueler-Furman O. Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions? Proteins 2010; 78: 3140-3149.
18. Qureshi NM, Coy DH, Garry RF, Henderson LA. Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. AIDS 1990; 4: 553-558.
19. Wild C, Dubay JW, Greenwell T, Baird T, Jr, Oas TG, McDanal C, Hunter E, Matthews T. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 1994; 91: 12676-12680.
20. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retrov 1993; 9: 1051-1053.
21. Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. Antiviral Res 2010; 86: 172-179.
22. Hrobowski YM, Garry RF, Michael SF. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2005; 2: 1-10.
23. Costin JM, Jenwitheesuk E, Lok SM, Hunsperger E, Conrads KA, Fontaine KA, Rees CR, Rossmann MG, Isern S, Samudrala R, Michael SF. Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLOS Negl Trop Dis 2010; 4: 1-11.
24. Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR. Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection. Antimicrob Agents Chemother 2009; 53: 987-996.
25. Galdiero S, Vitiello M, D'Isanto M, Falanga A, Cantisani M, Browne H, Pedone C, Galdiero M. The identification and characterization of fusogenic domains in herpes virus glycoprotein B molecules. Chembiochemistry 2008; 9: 758-767.
26. Melnik LI, Garry RF, Morris CA. Peptide inhibition of human cytomegalovirus infection. Virol J 2011; 8: 1-11.
27. Wimley WC, White SH. Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol 1996; 3: 842-848.
28. Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 2003; 100: 6986-6991.
29. Bower MJ, Cohen FE, Dunbrack RL, Jr. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J Mol Biol 1997; 267: 1268-1282.
30. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1995; 117: 5179-5197.
31. AMBER version 11. San Francisco: University of California; 2010.
32. Samudrala R, Moult J. An all-atom distance-dependent conditional probability discriminatory function for protein structure prediction. J Mol Biol 1998; 275: 893-914.
33. Yang Y, Zhou Y. Specific interactions for ab initio folding of protein terminal regions with secondary structures. Proteins 2008; 72: 793-803.
34. Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH. Equation of state calculations by fast computing machine. J Chem Phys 1953; 21: 1087-1092.
35. Caffrey M. Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop. Biochim Biophys Acta 2001; 1536: 116-122.
36. Wang W, Weiss CD. Inhibitors that target fusion. In: Reeves JD, Derdeyn CA, editors. Entry inhibitors in HIV therapy. Basel, Switzerland: Birkhäuser Verlag; 2007. pp 79-86.
37. Steffen I, Pöhlmann S. Peptide-based inhibitors of the HIV envelope protein and other Class I viral fusion proteins. Curr Pharm Des 2010; 16: 1143-1158.
38. Douglas NW, Munro GH, Daniels RS. HIV/SIV glycoproteins: structure-function relationships. J Mol Biol 1997; 273: 122-149.
39. Yang Y, Zhou Y. Ab initio folding of terminal segments with secondary structures reveals the fine difference between two closely related all-atom statistical energy functions. Protein Sci 2008; 17: 1212-1219.
40. Jenwitheesuk E, Samudrala R. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure. Antivir Ther 2005; 10: 893-900.
41. Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, Yang HO, Tan WL, Liu R, Yu M, Ge BX, Zhu QY, Qin ED, Guo YJ, Qin CF. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One 2011; 6: e16059.1-e16059.8.
42. Schmidt AG, Yang PL, Harrison SC. Peptide inhibitors of flavivirus entry derived from the E protein stem. J Virol 2010; 84: 12549-12554.
43. Schmidt AG, Yang PL, Harrison SC. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PLoS Pathog 2010; 6: e1000851.1-e1000851.11.
44. Liao M, Kielian M. Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J Cell Biol 2005; 171: 111-120.
45. Mazumder R, Hu ZZ, Vinayaka CR. Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines. Virus Genes 2007; 35: 175-186.
46. Nemésio H, Palomares-Jerez F, Villalaín J. The membrane-active regions of the dengue virus proteins C and E. Biochim Biophys Acta 2011; 1808: 2390-2402.